Nancy U Lin

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Response assessment criteria for brain metastases: proposal from the RANO group
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA Electronic address
    Lancet Oncol 16:e270-8. 2015
  2. pmc Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography I
    Nancy U Lin
    Nancy U Lin, Hao Guo, Nicole Ryabin, Julie S Najita, William T Barry, Ian E Krop, Eric P Winer, and Annick D Van den Abbeele, Dana Farber Cancer Institute Andrea L Richardson and Annick D Van den Abbeele, Brigham and Women s Hospital, Boston, MA Jeffrey T Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT Ingrid A Mayer and Carlos L Arteaga, Vanderbilt Ingram Cancer Center, Nashville, TN Carla I Falkson, University of Alabama, Birmingham, AL Timothy J Hobday, Mayo Clinic, Rochester, MN E Claire Dees, University of North Carolina, Chapel Hill, NC Rita Nanda, University of Chicago, Chicago, IL Mothaffar F Rimawi, Baylor College of Medicine, Houston, TX and Antonio C Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
    J Clin Oncol 33:2623-31. 2015
  3. pmc Breast cancer brain metastases: new directions in systemic therapy
    Nancy U Lin
    Dana Farber Cancer Institute, Boston, MA, USA
    Ecancermedicalscience 7:307. 2013
  4. pmc Targeted therapies in brain metastases
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Curr Treat Options Neurol 16:276. 2014
  5. doi request reprint A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
    Nancy U Lin
    Harvard Medical School, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 142:405-14. 2013
  6. doi request reprint Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Lancet Oncol 14:e407-16. 2013
  7. doi request reprint Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA Electronic address
    Lancet Oncol 14:e396-406. 2013
  8. doi request reprint A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    N U Lin
    Department of Medical Oncology, Division of Women s Cancers, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Breast Cancer Res Treat 139:403-10. 2013
  9. doi request reprint International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast 22:203-10. 2013
  10. pmc Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:5463-72. 2012

Detail Information

Publications64

  1. doi request reprint Response assessment criteria for brain metastases: proposal from the RANO group
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA Electronic address
    Lancet Oncol 16:e270-8. 2015
    ..The proposed criteria will hopefully facilitate the development of novel approaches to this difficult problem by providing more uniformity in the assessment of CNS metastases across trials. ..
  2. pmc Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography I
    Nancy U Lin
    Nancy U Lin, Hao Guo, Nicole Ryabin, Julie S Najita, William T Barry, Ian E Krop, Eric P Winer, and Annick D Van den Abbeele, Dana Farber Cancer Institute Andrea L Richardson and Annick D Van den Abbeele, Brigham and Women s Hospital, Boston, MA Jeffrey T Yap, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT Ingrid A Mayer and Carlos L Arteaga, Vanderbilt Ingram Cancer Center, Nashville, TN Carla I Falkson, University of Alabama, Birmingham, AL Timothy J Hobday, Mayo Clinic, Rochester, MN E Claire Dees, University of North Carolina, Chapel Hill, NC Rita Nanda, University of Chicago, Chicago, IL Mothaffar F Rimawi, Baylor College of Medicine, Houston, TX and Antonio C Wolff, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
    J Clin Oncol 33:2623-31. 2015
    ..We tested the combination in the earlier-line setting and explored the predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) for clinical outcomes...
  3. pmc Breast cancer brain metastases: new directions in systemic therapy
    Nancy U Lin
    Dana Farber Cancer Institute, Boston, MA, USA
    Ecancermedicalscience 7:307. 2013
    ....
  4. pmc Targeted therapies in brain metastases
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Curr Treat Options Neurol 16:276. 2014
    ....
  5. doi request reprint A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
    Nancy U Lin
    Harvard Medical School, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 142:405-14. 2013
    ..Given the high ORR, concurrent lapatinib-WBRT could still be considered for future study with careful safety monitoring. ..
  6. doi request reprint Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Lancet Oncol 14:e407-16. 2013
    ..In this report, the second in a two-part series, we review clinical trials of brain metastases in relation to measures of clinical benefit and provide a framework for the design and conduct of future trials. ..
  7. doi request reprint Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA Electronic address
    Lancet Oncol 14:e396-406. 2013
    ..In this two-part series, we review the state of clinical trials of brain metastases and suggest a consensus recommendation for the development of criteria for future clinical trials. ..
  8. doi request reprint A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    N U Lin
    Department of Medical Oncology, Division of Women s Cancers, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Breast Cancer Res Treat 139:403-10. 2013
    ..Additionally, unacceptable toxicity was observed, at rates greater than previously reported with vinorelbine/trastuzumab or vinorelbine/bevacizumab doublet combinations...
  9. doi request reprint International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast 22:203-10. 2013
    ..Moving forward, enhanced efforts to document quality of life over time should be made in order to more fully evaluate the risk/benefit ratio of available options...
  10. pmc Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:5463-72. 2012
    ..The objective of this study was to describe clinicopathologic features, patterns of recurrence, and survival according to breast cancer subtype with a focus on triple-negative tumors...
  11. pmc Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 113:2638-45. 2008
    ..The purpose of the current study was to characterize the outcomes of patients with metastatic triple-negative breast cancers, including the risk and clinical consequences of central nervous system (CNS) recurrence...
  12. doi request reprint Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
    Nancy U Lin
    Division of Women s Cancers, Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    J Neurooncol 105:613-20. 2011
    ..The combination of lapatinib plus topotecan was not active and was associated with excess toxicity...
  13. doi request reprint Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline
    Naren Ramakrishna
    Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando Edith A Perez, Mayo Clinic, Jacksonville Jennifer Levinson, Ponte Vedra Beach, FL Sarah Temin, American Society of Clinical Oncology, Alexandria, VA Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center Francisco J Esteva, New York University Cancer Institute, New York Jeffrey J Kirshner, Hematology Oncology Associates of Central New York, East Syracuse, NY Jennie R Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA Nancy E Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA Sharon H Giordano and Ana M Gonzalez Angulo, University of Texas MD Anderson Cancer Center, Houston Debra A Patt, Texas Oncology, Austin, TX Ian Krop, Eric P Winter, and Nancy U Lin, Dana Farber Cancer Institute, Boston, MA and Jane Perlmutter, Ann Arbor, MI
    J Clin Oncol 32:2100-8. 2014
    ..To provide formal expert consensus-based recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer...
  14. doi request reprint Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers
    Ines Vaz-Luis
    Dana Farber Cancer Institute, Boston, MA, USA
    Breast Cancer Res Treat 155:569-78. 2016
    ..Further studies to assess reasons for the observed wide variation are warranted. ..
  15. pmc Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1993-9. 2008
    ..We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases...
  16. doi request reprint Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases
    Michael A Dyer
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 83:e479-86. 2012
    ..In this retrospective study, we report on outcomes and prognostic factors for patients treated with stereotactic radiosurgery (SRS) for breast cancer brain metastases...
  17. ncbi request reprint New insights and emerging therapies for breast cancer brain metastases
    Elgene Lim
    Women s Cancers Program, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 26:652-9, 663. 2012
    ..Finally, we will review published and current prospective trials of systemic therapies specifically for BCBM, including novel pathway-specific therapies...
  18. doi request reprint Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:1452-9. 2009
    ..The current study was done to further evaluate the CNS activity of lapatinib. The study was later amended to allow patients who progressed on lapatinib the option of receiving lapatinib plus capecitabine...
  19. pmc Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, Breast Oncology Center, Boston, MA 02215, USA
    Clin Breast Cancer 13:254-63. 2013
    ..In this retrospective study, we investigated the clinicopathological features associated with prolonged first-line trastuzumab-based treatment duration...
  20. pmc A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases
    Rachel A Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 11:376-83. 2011
    ..We observed modest activity with a central nervous system objective response rate of 13.3%; however, median PFS was disappointing. Further studies should focus on other agents to treat this challenging clinical problem...
  21. pmc Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study
    Elizabeth Bullitt
    Computer Assisted Surgery and Imaging Laboratory, University of North Carolina, 247 Wing E, CB 7062, Chapel Hill, NC 27599, USA
    Radiology 245:824-30. 2007
    ....
  22. pmc Variation in Additional Breast Imaging Orders and Impact on Surgical Wait Times at a Comprehensive Cancer Center
    Mehra Golshan
    Department of Surgery, Brigham and Women s Hospital, Boston, MA, USA
    Ann Surg Oncol 22:S428-34. 2015
    ..We sought to evaluate the frequency of additional imaging orders by breast surgeons and to evaluate the impact of this supplementary imaging on timeliness of surgery...
  23. pmc Updates in the management of brain metastases
    Nils D Arvold
    St Luke s Radiation Oncology Associates, St Luke s Cancer Center, Whiteside Institute for Clinical Research and University of Minnesota Duluth, Duluth, Minnesota N D A Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts E Q L, P Y W Harvard Medical School, Boston, Massachusetts E Q L, B M A, N U L, I F D, P Y W Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, Maryland M P M Department of Medical Oncology, City of Hope, Duarte, California K M Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts B M A Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts N U L Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, North Carolina C K A Department of Neurology Neuro Oncology, University of Turin, Turin, Italy R S Division of Medical Oncology, University of Colorado Denver, Denver, Colorado D R C Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio M A V Department of Neurosurgery
    Neuro Oncol 18:1043-65. 2016
    ....
  24. pmc Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    Cancer 121:1937-48. 2015
    ..The authors examined the types and costs of adjuvant chemotherapy received among patients with stage I breast cancer...
  25. ncbi request reprint Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Invest New Drugs 25:369-75. 2007
    ..Although CT-2103 had activity in this small study, neurotoxicity and hypersensitivity reactions were more frequent in this patient population than expected, and led to early termination of the trial...
  26. doi request reprint Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype
    Nils D Arvold
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Breast Cancer Res Treat 136:153-60. 2012
    ..Women with DM from these two BC subtypes have a high incidence of BM with a short latency, suggesting an ideal target population for trials evaluating the utility of MRI screening...
  27. pmc A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    Nancy U Lin
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast Cancer Res Treat 133:1057-65. 2012
    ..4%) and rash (9.8%). Afatinib monotherapy was associated with promising clinical activity in extensively pretreated HER2-positive breast cancer patients who had progressed following trastuzumab treatment...
  28. doi request reprint Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 159:151-62. 2016
    ..Strategies to optimize care for older patients and to eliminate treatment disparities are urgently needed. ..
  29. doi request reprint Racial differences in outcomes for patients with metastatic breast cancer by disease subtype
    Ines Vaz-Luis
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 151:697-707. 2015
    ..white) patients. Among women with de novo metastatic breast cancer, racial differences in survival were only apparent for those with inferred HER2-positive tumors. Further study of how treatment patterns affect outcomes is warranted. ..
  30. pmc The Influence of Radiology Image Consultation in the Surgical Management of Breast Cancer Patients
    Melissa Anne Mallory
    Department of Surgery, Dana Farber Brigham and Women s Cancer Center, Boston, MA, USA
    Ann Surg Oncol 22:3383-8. 2015
    ..We sought to identify the incidence of additional imaging requests and the effect additional imaging has on patients' ultimate surgical management...
  31. pmc Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study
    Ines Vaz-Luis
    Ines Vaz Luis, Nancy U Lin, Eric P Winer, and Rachel A Freedman, Dana Farber Cancer Institute Nancy L Keating, Harvard Medical School Nancy L Keating and Huichuan Lii, Brigham and Women s Hospital, Boston, MA and Ines Vaz Luis, Instituto de Medicina Molecular, Lisbon, Portugal
    J Clin Oncol 32:927-34. 2014
    ..Few data are available regarding adjuvant trastuzumab use in older women with early-stage breast cancer. We examined rates and predictors of adjuvant trastuzumab completion and cardiac events in this population...
  32. doi request reprint Heterogeneity of breast cancer and implications of adjuvant chemotherapy
    A Rab Razzak
    Dana Farber Cancer Institute, Boston, MA, USA
    Breast Cancer 15:31-4. 2008
    ..In the future, breast cancer treatment will be more targeted to the tumor and tailored to the individual with the use of genomic and clinical data...
  33. doi request reprint Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis
    Antonio Di Meglio
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 157:587-96. 2016
    ..A modest improvement in metastatic breast cancer median overall survival was observed, but was apparently limited to ductal carcinomas. ..
  34. doi request reprint Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study
    Romualdo Barroso-Sousa
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    Breast 30:136-140. 2016
    ..The necessity of using granulocyte-colony stimulating factor (G-CSF) during dose-dense (DD) paclitaxel (T) after doxorubicin and cyclophosphamide (AC) is unclear...
  35. ncbi request reprint Factors Associated With Delays in Chemotherapy Initiation Among Patients With Breast Cancer at a Comprehensive Cancer Center
    Katya Losk
    From Department of Medical Oncology and Quality and Patient Safety, Dana Farber Cancer Institute, Boston, Massachusetts Oncoclinicas, Sao Paulo, Brazil Department of General Surgery, Istanbul Medical School, Istanbul, Turkey and Department of Surgery, Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, Massachusetts
    J Natl Compr Canc Netw 14:1519-1526. 2016
    ..National guidelines endorse time-dependent quality metrics for breast cancer care. We examined factors associated with delays in chemotherapy initiation at an NCI-Designated Comprehensive Cancer Center...
  36. pmc Prospective clinical experience with research biopsies in breast cancer patients
    Ines Vaz-Luis
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 142:203-9. 2013
    ..This supports continued efforts to study tissue samples at multiple points in a patient's disease course...
  37. doi request reprint Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy
    Rachel A Freedman
    Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA
    Breast Cancer Res Treat 145:491-501. 2014
    ..Non-standard chemotherapy was associated with fewer toxicity-related hospitalizations but worse survival. Further exploration of treatment toxicities and outcomes for older women with HER2-positive breast cancer is warranted. ..
  38. pmc Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study
    Ines Vaz-Luis
    Ines Vaz Luis, Melissa E Hughes, Harold J Burstein, Jane C Weeks, Eric P Winer, and Nancy U Lin, Dana Farber Cancer Institute Beverly Moy, Massachusetts General Hospital, Boston, MA Ines Vaz Luis, Instituto de Medicina Molecular, Lisbon, Portugal Rebecca A Ottesen and Rizvan Mamet, City of Hope, Duarte Hope S Rugo, University of California, San Francisco, San Francisco, CA Stephen B Edge, Roswell Park Cancer Institute, Buffalo, NY Stephen B Edge, Baptist Cancer Center, Memphis, TN and Ana M Gonzalez Angulo and Richard L Theriault, University of Texas MD Anderson Cancer Center, Houston, TX
    J Clin Oncol 32:2142-50. 2014
    ..Treatment decisions for patients with T1a,bN0M0 breast cancer are challenging. We studied the time trends in use of adjuvant chemotherapy and survival outcomes among these patients...
  39. pmc Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
    Lyndsay N Harris
    Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Breast Cancer Res 8:R66. 2006
    ..We analyzed data from CALGB 9342, which tested three doses of paclitaxel in women with advanced disease, to determine whether response and outcomes differed according to HER2, hormone receptor, and p53 status...
  40. doi request reprint Quality of life in long-term survivors of metastatic breast cancer
    Jane L Meisel
    Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Clin Breast Cancer 12:119-26. 2012
    ..Psychosocial distress is common after a diagnosis of breast cancer. Little is known about the psychosocial adjustment of women living long term with metastatic breast cancer...
  41. ncbi request reprint CNS metastases in breast cancer
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 22:3608-17. 2004
    ..Studies specifically targeted toward this group of patients are needed...
  42. ncbi request reprint Novel approaches to advanced breast cancer: bevacizumab and lapatinib
    Erica L Mayer
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Natl Compr Canc Netw 5:314-23. 2007
    ..This review highlights recent advances with the anti-vascular endothelial growth factor antibody, bevacizumab, and the dual kinase inhibitor, lapatinib, in the treatment of metastatic breast cancer...
  43. pmc Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer
    Nadine Tung
    Nadine Tung, Beth Israel Deaconess Medical Center Nancy U Lin, Eric P Winer, and Judy E Garber, Dana Farber Cancer Institute Nadine Tung, Nancy U Lin, Eric P Winer, and Judy E Garber, Harvard Medical School, Boston, MA and John Kidd, Brian A Allen, Nanda Singh, Richard J Wenstrup, and Anne Renee Hartman, Myriad Genetic Laboratories, Inc, Salt Lake City, UT
    J Clin Oncol 34:1460-8. 2016
    ....
  44. doi request reprint Randomized trial of a physical activity intervention in women with metastatic breast cancer
    Jennifer A Ligibel
    Breast Oncology Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    Cancer 122:1169-77. 2016
    ....
  45. ncbi request reprint Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy
    Davinia S E Seah
    From the aDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, and bDepartment of Medical Oncology, The Ohio State University College of Medicine, Columbus, Ohio
    J Natl Compr Canc Netw 12:71-80. 2014
    ..The role of advanced (greater than third) chemotherapy lines in improving survival of all patients with MBC warrants further study. ..
  46. pmc High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer
    Sandro Santagata
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 108:18378-83. 2011
    ..The findings indicate that HSF1 should be evaluated prospectively as an independent prognostic indicator in ER-positive breast cancer. HSF1 may ultimately be a useful therapeutic target in cancer...
  47. ncbi request reprint Brain metastases: the HER2 paradigm
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 13:1648-55. 2007
    ..Finally, new developments in systemic approaches to the treatment of CNS disease, including cytotoxic chemotherapy and targeted therapy, are explored...
  48. doi request reprint Internal mammary nodes in breast cancer: diagnosis and implications for patient management -- a systematic review
    Ronald C Chen
    Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 26:4981-9. 2008
    ..However, even in patients with visualized primary IMN drainage, the potential benefit of treatment should be balanced against the risk of added morbidity...
  49. doi request reprint Advances in adjuvant endocrine therapy for postmenopausal women
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Mayer 232, Boston, MA 02115, USA
    J Clin Oncol 26:798-805. 2008
    ..We outline controversies in choosing the optimal endocrine approach, and we discuss selected ongoing studies. Finally, we highlight future research directions, such as the need to understand host and tumor heterogeneity...
  50. pmc Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer
    Elizabeth Bullitt
    CASILab, CB 7062, University of North Carolina, Chapel Hill, NC 27599, USA
    Med Image Comput Comput Assist Interv 9:561-8. 2006
    ..In this preliminary study of 16 patients undergoing treatment for metastatic breast cancer we conclude that vessel shape may predict tumor response several months in advance of traditional methods...
  51. doi request reprint Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline
    Sharon H Giordano
    Sharon H Giordano and Ana M Gonzalez Angulo, University of Texas MD Anderson Cancer Center, Houston Debra A Patt, Texas Oncology, Austin, TX Sarah Temin, American Society of Clinical Oncology, Alexandria, VA Jeffrey J Kirshner, Hematology Oncology Associates of Central New York, East Syracuse Sarat Chandarlapaty and Shanu Modi, Memorial Sloan Kettering Cancer Center Francisco J Esteva, New York University Cancer Institute, New York, NY Jennie R Crews, PeaceHealth St Joseph Cancer Center, Bellingham, WA Nancy E Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA Ian Krop, Nancy U Lin, and Eric P Winer, Dana Farber Cancer Institute, Boston, MA Jennifer Levinson, Ponte Vedra Beach Edith A Perez, Mayo Clinic, Jacksonville Naren Ramakrishna, University of Florida Health Cancer Center at Orlando Health, Orlando, FL and Jane Perlmutter, Ann Arbor, MI
    J Clin Oncol 32:2078-99. 2014
    ..To provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer...
  52. doi request reprint Attitudes of patients with metastatic breast cancer toward research biopsies
    D S Seah
    Deparment of Medical Oncology, Dana Farber Cancer Institute, Boston MA02215, USA
    Ann Oncol 24:1853-9. 2013
    ..Research studies involving human tissue are increasingly common. However, patients' attitudes toward research biopsies are not well characterized, particularly when the biopsies are carried out outside the context of therapeutic trials...
  53. pmc Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer
    Jennifer Y Wo
    Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Oncol 29:2619-27. 2011
    ..In particular, we evaluated whether very small tumor size may predict for increased BCSM relative to larger tumors in patients with extensive LN involvement...
  54. pmc Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
    Rachel A Freedman
    Rachel A Freedman, Rebecca S Gelman, Christina Herold, Nicole Ryabin, Sarah Farooq, Elizabeth Lawler, Ian E Krop, Eric P Winer, and Nancy U Lin, Dana Farber Cancer Institute Beverly Moy, Massachusetts General Hospital Alarice Lowe and Nathalie Y R Agar, Brigham and Women s Hospital, Boston, MA Jeffrey S Wefel, Kenneth R Hess, and Nuhad Ibrahim, The University of Texas MD Anderson Cancer Center Polly A Niravath and Mothaffar F Rimawi, Baylor College of Medicine, Houston, TX Michelle E Melisko, University of California, San Francisco, San Francisco, CA Roisin M Connolly and Antonio C Wolff, Johns Hopkins University, Baltimore, MD Catherine H Van Poznak, University of Michigan, Ann Arbor, MI Shannon L Puhalla, University of Pittsburgh Cancer Institute and Magee Women s Hospital, Pittsburgh, PA Kimberly L Blackwell, Duke University Medical Center, Durham, NC and Minetta C Liu, Mayo Clinic, Rochester, MN
    J Clin Oncol 34:945-52. 2016
    ..We evaluated the efficacy of treatment with neratinib in patients with HER2-positive breast cancer brain metastases in a multicenter, phase II open-label trial...
  55. pmc TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
    Carey Anders
    Lineberger Comprehensive Cancer Center, University of North Carolina, 450 West Drive, Campus Box 7295, Chapel Hill, NC, 27599, USA
    Breast Cancer Res Treat 146:557-66. 2014
    ..This study suggests a modest benefit of irinotecan plus iniparib in progressive TNBC-BM. More importantly, this trial design is feasible and lays the foundation for additional studies for this treatment-refractory disease. ..
  56. doi request reprint Local control after fractionated stereotactic radiation therapy for brain metastases
    Selvan Rajakesari
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, Boston, MA, USA
    J Neurooncol 120:339-46. 2014
    ..3 %). SRT appears to be a safe and reasonably effective technique to treat brain metastases deemed less suitable for SRS, though dose intensification strategies may further improve local control...
  57. pmc New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Breast Cancer Res 6:204-10. 2004
    ....
  58. doi request reprint Salvage stereotactic radiosurgery for breast cancer brain metastases: outcomes and prognostic factors
    Paul J Kelly
    Department of Radiation Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts, USA
    Cancer 118:2014-20. 2012
    ..The goal of this study was to analyze clinical outcomes and prognostic factors for survival in the salvage setting...
  59. pmc Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer
    Brittany L Bychkovsky
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 21:1495-1501. 2016
    ..Despite guideline recommendations, baseline laboratory testing and advanced imaging are widely ordered in clinical practice to stage asymptomatic patients with clinical stage II breast cancer (BC)...
  60. pmc Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer
    Davinia S Seah
    Dana Farber Cancer Institute, Boston, Massachusetts, USA Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA Memorial Sloan Kettering Cancer Center, New York, New York, USA Brigham and Women s Hospital, Boston, Massachusetts, USA Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 20:992-1000. 2015
    ..Tissue from research biopsies provides access to insights into tumor biology. We aimed to determine medical oncologists' (MOs') attitudes toward research biopsies in patients with metastatic breast cancer (MBC)...
  61. doi request reprint Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis
    Davinia Se Seah
    Dana Farber Cancer Institute, Department of Medical Oncology, Boston, Massachusetts, USA
    J Community Support Oncol 12:347-54. 2014
    ..Little is known about the informational needs and quality of life (QOL) of patients with metastatic breast cancer (MBC) within the first year of their diagnosis...
  62. doi request reprint Understanding process-of-care delays in surgical treatment of breast cancer at a comprehensive cancer center
    Mehra Golshan
    Department of Surgery, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA
    Breast Cancer Res Treat 148:125-33. 2014
    ..Cancer centers may consider investing in efforts to measure and improve the timeliness of cancer care. ..
  63. pmc Metabolic activity in the insular cortex and hypothalamus predicts hot flashes: an FDG-PET study
    Hadine Joffe
    Center for Women s Mental Health, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston Massachusetts 02114, USA
    J Clin Endocrinol Metab 97:3207-15. 2012
    ..Previous studies have implicated the insula during the perception of hot flashes and the hypothalamus in thermoregulatory dysfunction...
  64. pmc The ethical use of mandatory research biopsies
    Erin M Olson
    Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA
    Nat Rev Clin Oncol 8:620-5. 2011
    ....